BioNTech Nears First US Oncology Filing as ASCO Data Lends Weight to Pipeline Ambitions
Published on 06/01/2026 at 04:50 | Redaktion boerse-global.de
BioNTech is positioning itself for what could be its most significant regulatory milestone since the COVID-19 shots: a Biologics License Application for the antibody-drug conjugate Trastuzumab Pamirtecan (BNT323), targeted for submission to the FDA later this year. The candidate already carries Fast Track and Breakthrough Therapy designations for endometrial cancer, and a Phase 2 trial delivered a 47.9% objective response rate with a median progression-free survival of 8.1 months. A Chinese filing with the NMPA is already in play. If successful, the US application would mark BioNTech’s first oncology approval in America.
The regulatory push comes as the company fleshes out its broader cancer pipeline with data from the ASCO annual meeting. Two oral presentations caught the market’s attention. The bispecific antibody pumitamig, in the ROSETTA-Lung-02 study, showed encouraging anti-tumor activity when combined with chemotherapy in first-line non-small cell lung cancer patients. It was the third consistent dataset for the combination, following earlier positive reads in small cell lung cancer and triple-negative breast cancer. A Phase 3 trial now pits pumitamig plus chemo directly against pembrolizumab plus chemo.
The second presentation centered on gotistobart, the CTLA-4 antibody co-developed with OncoC4. In the Phase 2 PRESERVE-004 trial, the drug produced durable activity in heavily pre-treated patients with platinum-resistant ovarian cancer, alongside clinically meaningful overall survival data and a manageable safety profile. Gotistobart had previously been best known for its role in squamous non-small cell lung cancer, where a global Phase 3 study is already recruiting. The ovarian cancer data extends the candidate’s reach into a second tumor type, broadening the program’s clinical footprint.
Should investors sell immediately? Or is it worth buying BioNTech?
Financially, the transition from pandemic-era vaccine revenues continues to weigh on the income statement. First-quarter 2026 revenue came in at €118.1 million, down from €182.8 million a year earlier, nearly entirely due to declining COVID-19 jab sales. The net loss widened to €531.9 million, with research spending climbing to €557.0 million — gotistobart and pumitamig were named as the primary cost drivers. For the full year, BioNTech has guided for revenue between €2.0 billion and €2.3 billion, down from €2.9 billion in 2025.
The balance sheet remains a point of strength. Liquid assets and securities stood at €16.8 billion at the end of March, giving the company ample runway to develop its oncology pipeline without financial pressure. That war chest is being deployed aggressively: BioNTech plans to have 15 active Phase 3 studies by year-end, with five new trials for pumitamig alone and seven late-stage data readouts scheduled in 2026. The next concrete milestone comes from PRESERVE-003, the pivotal Phase 3 study of gotistobart in metastatic squamous lung cancer, with interim results expected later this year.
Analyst sentiment is cautiously bullish. Of the 17 analysts covering the stock, the consensus rating is “Buy,” with a price target equivalent to roughly $125 — a 38% upside from current levels. The shares closed the Friday after ASCO at €82.35, up 2.68% on the session, just above the 50-day moving average but still 19% below the 52-week high of €101.90. The stock has been roughly flat since January.
All eyes now turn to the second-quarter earnings due on August 4, and any clarity on the BLA submission timeline. The ASCO data have provided clinical signals. Whether they translate into sustained share price momentum will depend on the regulatory path that lies ahead.
Ad
BioNTech Stock: New Analysis - 1 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
